Fixed Versus Body-Sized-Based Dosing of Monoclonal Antibodies

Area of Science:

• Pharmacology
• Drug Development
• Clinical Trials

Background:

• Monoclonal antibodies represent a growing class of novel drug approvals.
• Current labeling often uses body-size-based dosing without clear justification.
• This poses challenges for patients outside typical body habitus ranges.

Purpose of the Study:

• To advocate for fixed-dose regimens in early-phase monoclonal antibody trials.
• To highlight the benefits of fixed-dose over body-size-based administration.

Main Methods:

• Literature review and analysis of current drug approval trends.
• Evaluation of the practical implications of different dosing strategies.

Main Results:

• Body-size-based dosing presents challenges for patient populations with extreme body habitus.
• Fixed-dose regimens offer advantages in standardization, error reduction, and practicality.

Conclusions:

• Fixed-dose regimens should be the initial approach for monoclonal antibodies in Phase 1 clinical trials.
• Transitioning to fixed-dose strategies can enhance safety and efficiency in drug administration.